Company Overview

Perspective Therapeutics, Inc. (Nasdaq: CATX) is a U.S.-based radiopharmaceutical company focused on developing targeted alpha-particle therapies for the treatment of cancer. The company operates within the biotechnology, precision oncology, and nuclear medicine industries, with a strategic emphasis on integrating isotope production, radiochemistry, and targeted drug development. Perspective Therapeutics develops radiopharmaceutical candidates designed to selectively deliver radioactive isotopes to tumor cells while limiting exposure to surrounding healthy tissue.

The company’s primary revenue and value drivers are its proprietary targeted alpha therapy pipeline, isotope supply capabilities, and radiopharmaceutical manufacturing infrastructure. Perspective Therapeutics has focused on therapies using lead-212 (Pb-212), an alpha-emitting radioisotope considered promising for oncology applications due to its high-energy, short-range radiation profile. The company evolved from Cellectar Biosciences, Inc., which historically focused on phospholipid drug conjugate technology, and rebranded as Perspective Therapeutics following strategic acquisitions and a transition toward radiopharmaceutical oncology. Public filings and investor materials indicate that the company’s positioning is differentiated by its vertically integrated approach combining isotope production, drug development, and manufacturing capabilities.

Business Operations

Perspective Therapeutics operates primarily through radiopharmaceutical research, development, isotope processing, and manufacturing activities. Its operations are centered on developing targeted alpha therapies for solid tumors and neuroendocrine cancers, supported by proprietary radiochemistry platforms and isotope handling infrastructure. The company’s development programs include candidates targeting somatostatin receptor-positive tumors and melanoma-associated antigens, among others. Revenue generation has historically been limited, as the company remains in the clinical development stage, though it has pursued strategic collaborations, isotope supply arrangements, and manufacturing expansion initiatives.

The company maintains operations in the United States with infrastructure related to isotope handling and radiopharmaceutical manufacturing. Perspective Therapeutics strengthened its operational platform through acquisitions including Viewpoint Molecular Targeting, Inc. and assets associated with isotope production and radiopharmaceutical development. The company has also invested in current Good Manufacturing Practice (cGMP) manufacturing capabilities and isotope supply chain control, which management has identified as strategically important given industry-wide isotope shortages and increasing demand for radioligand therapies.

Strategic Position & Investments

Perspective Therapeutics’ strategic direction is focused on becoming a vertically integrated radiopharmaceutical oncology company with control over isotope supply, drug development, and manufacturing. The company has invested heavily in Pb-212-based targeted alpha therapies and associated production infrastructure. Strategic initiatives have included expanding isotope generation capacity, advancing clinical-stage oncology programs, and building internal radiopharmaceutical manufacturing capabilities intended to support future commercial scaling.

A major strategic development was the acquisition of Viewpoint Molecular Targeting, Inc., which broadened Perspective Therapeutics’ radiopharmaceutical pipeline and technical expertise. The company has also pursued investments in isotope production technologies and manufacturing facilities to strengthen supply reliability. Public disclosures indicate continued emphasis on emerging targeted alpha therapy markets, where radiopharmaceutical companies are competing to establish differentiated oncology platforms. Management has consistently highlighted the importance of vertical integration and isotope access as key competitive advantages in the evolving nuclear medicine sector.

Geographic Footprint

Perspective Therapeutics is headquartered in Seattle, Washington, and primarily operates in the United States. Its activities include clinical development, isotope processing, manufacturing development, and corporate operations. The company’s operational footprint also includes facilities and partnerships associated with radiopharmaceutical production and research activities across multiple U.S. locations.

Although Perspective Therapeutics does not currently maintain the same global commercial footprint as larger pharmaceutical companies, its clinical and strategic activities are connected to broader international nuclear medicine supply chains. The radiopharmaceutical industry relies on globally sourced isotopes, specialized logistics networks, and regulatory coordination across regions including North America and parts of Europe. The company’s long-term strategy suggests an intention to support broader international clinical and commercial reach as its pipeline advances.

Leadership & Governance

Perspective Therapeutics is led by executives with backgrounds in biotechnology, oncology, radiopharmaceuticals, and pharmaceutical operations. Leadership has emphasized advancing targeted alpha therapies through integrated manufacturing, isotope access, and clinical development capabilities. Governance and strategic direction are guided through public company oversight structures disclosed in SEC filings and investor communications.

Key executives include:

• Thijs Spoor – Chief Executive Officer
• Juan Graham – Chief Financial Officer
• Dr. Markus Puhlmann – Chief Medical Officer
• John Zehner – Chief Business Officer
• Dr. Michael Schultz – Chief Operating Officer

The company’s leadership strategy has focused on expanding radiopharmaceutical infrastructure, accelerating oncology clinical programs, and positioning Perspective Therapeutics as an integrated precision oncology platform within the targeted alpha therapy market.